Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest update is out from Shanghai Pharmaceuticals Holding Co ( (HK:2607) ).
Shanghai Pharmaceuticals Holding Co., Ltd. has announced its proposed 2025 Interim Profit Distribution Plan, which was approved by the board of directors. The company plans to distribute a cash dividend of RMB1.20 per ten shares, amounting to a total of RMB445,003,417.08, representing 9.98% of the consolidated net profit for the first half of 2025. This plan is contingent upon shareholder approval at the upcoming general meeting. The announcement reflects the company’s commitment to returning value to its shareholders and maintaining stable financial operations.
The most recent analyst rating on (HK:2607) stock is a Buy with a HK$13.50 price target. To see the full list of analyst forecasts on Shanghai Pharmaceuticals Holding Co stock, see the HK:2607 Stock Forecast page.
More about Shanghai Pharmaceuticals Holding Co
Shanghai Pharmaceuticals Holding Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating in the pharmaceutical industry. The company is primarily engaged in the production and distribution of pharmaceutical products and services, focusing on the Chinese market.
Average Trading Volume: 3,259,649
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$77.57B
Learn more about 2607 stock on TipRanks’ Stock Analysis page.